Alembic Pharmaceuticals Limited
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally. The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal healt… Read more
Alembic Pharmaceuticals Limited (APLLTD) - Net Assets
Latest net assets as of September 2025: ₹53.16 Billion INR
Based on the latest financial reports, Alembic Pharmaceuticals Limited (APLLTD) has net assets worth ₹53.16 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹83.97 Billion) and total liabilities (₹30.81 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹53.16 Billion |
| % of Total Assets | 63.31% |
| Annual Growth Rate | 22.72% |
| 5-Year Change | 2.42% |
| 10-Year Change | 224.24% |
| Growth Volatility | 22.92 |
Alembic Pharmaceuticals Limited - Net Assets Trend (2011–2025)
This chart illustrates how Alembic Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alembic Pharmaceuticals Limited (2011–2025)
The table below shows the annual net assets of Alembic Pharmaceuticals Limited from 2011 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹51.90 Billion | +7.71% |
| 2024-03-31 | ₹48.18 Billion | +10.24% |
| 2023-03-31 | ₹43.70 Billion | -16.56% |
| 2022-03-31 | ₹52.38 Billion | +3.37% |
| 2021-03-31 | ₹50.67 Billion | +58.82% |
| 2020-03-31 | ₹31.90 Billion | +17.38% |
| 2019-03-31 | ₹27.18 Billion | +22.41% |
| 2018-03-31 | ₹22.20 Billion | +16.79% |
| 2017-03-31 | ₹19.01 Billion | +18.79% |
| 2016-03-31 | ₹16.01 Billion | +80.93% |
| 2015-03-31 | ₹8.85 Billion | +30.95% |
| 2014-03-31 | ₹6.76 Billion | +34.32% |
| 2013-03-31 | ₹5.03 Billion | +27.33% |
| 2012-03-31 | ₹3.95 Billion | +33.77% |
| 2011-03-31 | ₹2.95 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alembic Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4394220000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹43.94 Billion | 84.65% |
| Common Stock | ₹393.10 Million | 0.76% |
| Other Comprehensive Income | ₹87.80 Million | 0.17% |
| Other Components | ₹7.49 Billion | 14.42% |
| Total Equity | ₹51.91 Billion | 100.00% |
Alembic Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Alembic Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SFTCF
PINK:SFTCF
|
$447.95 Million |
|
IMMOFINANZ AG
VI:IIA
|
$448.18 Million |
|
Bravura Solutions Limited
PINK:BVSFF
|
$448.30 Million |
|
Accolade, Inc.
NASDAQ:ACCD
|
$448.32 Million |
|
Qingdao Doublestar Co Ltd
SHE:000599
|
$447.80 Million |
|
Guangdong LingXiao Pump Industry Co Ltd
SHE:002884
|
$447.71 Million |
|
Guangdong Jiaying Pharmaceutical Co Ltd
SHE:002198
|
$447.60 Million |
|
MilDef Group AB
ST:MILDEF
|
$447.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alembic Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 48,182,000,000 to 51,909,400,000, a change of 3,727,400,000 (7.7%).
- Net income of 5,834,200,000 contributed positively to equity growth.
- Dividend payments of 2,162,200,000 reduced retained earnings.
- Other comprehensive income increased equity by 55,400,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹5.83 Billion | +11.24% |
| Dividends Paid | ₹2.16 Billion | -4.17% |
| Other Comprehensive Income | ₹55.40 Million | +0.11% |
| Total Change | ₹- | 7.74% |
Book Value vs Market Value Analysis
This analysis compares Alembic Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.54x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 42.77x to 2.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-03-31 | ₹15.67 | ₹670.00 | x |
| 2012-03-31 | ₹20.94 | ₹670.00 | x |
| 2013-03-31 | ₹26.69 | ₹670.00 | x |
| 2014-03-31 | ₹35.84 | ₹670.00 | x |
| 2015-03-31 | ₹46.93 | ₹670.00 | x |
| 2016-03-31 | ₹84.90 | ₹670.00 | x |
| 2017-03-31 | ₹100.85 | ₹670.00 | x |
| 2018-03-31 | ₹117.77 | ₹670.00 | x |
| 2019-03-31 | ₹144.22 | ₹670.00 | x |
| 2020-03-31 | ₹170.78 | ₹670.00 | x |
| 2021-03-31 | ₹261.53 | ₹670.00 | x |
| 2022-03-31 | ₹266.46 | ₹670.00 | x |
| 2023-03-31 | ₹222.34 | ₹670.00 | x |
| 2024-03-31 | ₹245.12 | ₹670.00 | x |
| 2025-03-31 | ₹264.09 | ₹670.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alembic Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.24%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.74%
- • Asset Turnover: 0.86x
- • Equity Multiplier: 1.50x
- Recent ROE (11.24%) is below the historical average (24.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 28.92% | 7.12% | 1.42x | 2.86x | ₹558.59 Million |
| 2012 | 32.95% | 8.87% | 1.39x | 2.66x | ₹906.33 Million |
| 2013 | 32.86% | 10.87% | 1.45x | 2.08x | ₹1.15 Billion |
| 2014 | 41.88% | 13.75% | 1.69x | 1.80x | ₹2.15 Billion |
| 2015 | 31.98% | 13.75% | 1.25x | 1.86x | ₹1.94 Billion |
| 2016 | 44.99% | 23.05% | 1.27x | 1.54x | ₹5.60 Billion |
| 2017 | 21.21% | 12.98% | 1.16x | 1.41x | ₹2.13 Billion |
| 2018 | 18.59% | 13.18% | 0.79x | 1.78x | ₹1.91 Billion |
| 2019 | 21.49% | 14.85% | 0.82x | 1.76x | ₹3.12 Billion |
| 2020 | 25.74% | 18.00% | 0.77x | 1.86x | ₹5.07 Billion |
| 2021 | 22.63% | 21.26% | 0.80x | 1.32x | ₹6.40 Billion |
| 2022 | 9.95% | 9.82% | 0.74x | 1.36x | ₹-28.15 Million |
| 2023 | 7.83% | 6.05% | 0.91x | 1.41x | ₹-950.57 Million |
| 2024 | 12.78% | 9.89% | 0.97x | 1.34x | ₹1.34 Billion |
| 2025 | 11.24% | 8.74% | 0.86x | 1.50x | ₹643.26 Million |
Industry Comparison
This section compares Alembic Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alembic Pharmaceuticals Limited (APLLTD) | ₹53.16 Billion | 28.92% | 0.58x | $447.90 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |